{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:39Z","timestamp":1777374279705,"version":"3.51.4"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["GAUK1600317"],"award-info":[{"award-number":["GAUK1600317"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["SVV260412\/2017"],"award-info":[{"award-number":["SVV260412\/2017"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["SVV260414\/2017"],"award-info":[{"award-number":["SVV260414\/2017"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jpba.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T06:16:58Z","timestamp":1499494618000},"page":"378-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Current antiviral drugs and their analysis in biological materials \u2013 Part II: Antivirals against hepatitis and HIV viruses"],"prefix":"10.1016","volume":"147","author":[{"given":"Lucie","family":"Nov\u00e1kov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Pavl\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Chrenkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ond\u0159ej","family":"Martinec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"\u010cerven\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.07.003_bib0005","article-title":"Current antiviral drugs and their analysis in biological materials \u2013 part I: antivirals against respiratory and herpes viruses","author":"Nov\u00e1kov\u00e1","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jpba.2017.07.003_bib0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.07.003_bib0020","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.13095","article-title":"Managing drug\u2013drug interactions with new direct-acting antiviral agents in chronic hepatitis C","volume":"83","author":"Talavera Pons","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12977-015-0148-6","article-title":"An integrated map of HIV genome-wide variation from a population perspective","volume":"12","author":"Li","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0045","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/v7092857","article-title":"Genetic diversity and selective pressure in hepatitis C virus genotypes 1\u20136: significance for direct-acting antiviral treatment and drug resistance","volume":"7","author":"Cuypers","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jpba.2017.07.003_bib0050","first-page":"1351","article-title":"Hepatitis C: diagnosis and treatment","volume":"81","author":"Wilkins","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jpba.2017.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jpba.2017.07.003_bib0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/CMR.00124-13","article-title":"Viruses and human cancers: a long road of discovery of molecular paradigms","volume":"27","author":"White","year":"2014","journal-title":"Clin. Microbiol. Rev"},{"key":"10.1016\/j.jpba.2017.07.003_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis B virus-related cirrhosis: natural history and treatment","volume":"26","author":"Chu","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jpba.2017.07.003_bib0070","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/652283","article-title":"Causes of death in HIV\u20101-infected patients treated with antiretroviral therapy, 1996\u20132006: collaborative analysis of 13 HIV cohort studies","volume":"50","author":"Gill","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2017.07.003_bib0075","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jpba.2017.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1592\/phco.26.12.1745","article-title":"Entecavir a new nucleoside analog for the treatment of chronic hepatitis B infection","volume":"26","author":"Sims","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2017.07.003_bib0085","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","article-title":"Entecavir for the treatment of chronic hepatitis B virus infection","volume":"28","author":"Matthews","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2017.07.003_bib0095","first-page":"37","article-title":"Pediatric hepatitis B treatment","volume":"5","author":"Komatsu","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0105","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(95)91829-9","article-title":"Hepatitis B reactivation after lamivudine","volume":"346","author":"Honkoop","year":"1995","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jpba.2017.07.003_bib0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1345\/aph.1D362","article-title":"Adefovir dipivoxil in the treatment of chronic hepatitis B","volume":"38","author":"Rivkin","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jpba.2017.07.003_bib0115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen\u2014positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0125","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3310\/hta14suppl1-04","article-title":"Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection","volume":"14","author":"Jones","year":"2010","journal-title":"Health Technol. Assess. (Rockv)"},{"key":"10.1016\/j.jpba.2017.07.003_bib0135","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpba.2017.07.003_bib0150","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/AAC.00223-15","article-title":"Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.003_bib0155","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0160","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMe1513245","article-title":"Simple, effective, but out of reach? public health implications of HCV drugs","volume":"373","author":"Ward","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0165","unstructured":"European Centre for Disease Prevention and Control, Distribution of Antibacterials For Systemic Use (ATC group J01) in the community (primary care sector) in Austria, reporting year 2015, (n.d.). http:\/\/ecdc.europa.eu\/en\/healthtopics\/antimicrobial-resistance-and-consumption\/antimicrobial-consumption\/esac-net-database\/Pages\/consumption-rates-by-country.aspx (Accessed 25 April, 2017)."},{"key":"10.1016\/j.jpba.2017.07.003_bib0170","unstructured":"https:\/\/chemicalize.com\/ (Accessed 25 April, 2017)."},{"key":"10.1016\/j.jpba.2017.07.003_bib0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchromb.2014.11.004","article-title":"Rapid determination of lamivudine in human plasma by high-performance liquid chromatography","volume":"975","author":"Alebouyeh","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0180","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jssc.200900674","article-title":"Quantification of lamivudine in human plasma by hydrophilic interaction chromatography-tandem mass spectrometry","volume":"33","author":"Ji","year":"2010","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpba.2015.05.016","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients","volume":"114","author":"De Nicol\u00f2","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jchromb.2016.04.019","article-title":"Simultaneous determination of pradefovir, PMEA and tenofovir in HBV patient serum using liquid chromatography-tandem mass spectrometry and application to phase 2 clinical trial","volume":"1022","author":"Xiao","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0195","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jchromb.2010.06.024","article-title":"Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study","volume":"878","author":"Xiong","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0200","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1365\/s10337-010-1474-4","article-title":"A new LC\u2013MS\u2013MS method for quantitative analysis of adefovir, and its use for pharmacokinetic studies in healthy chinese volunteers","volume":"71","author":"Xie","year":"2010","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2017.07.003_bib0205","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/chromsci\/47.10.889","article-title":"Determination of Adefovir by LC-ESI-MS-MS and its application to a pharmacokinetic study in healthy chinese volunteers","volume":"47","author":"Zou","year":"2009","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/chromsci\/bmv172","article-title":"Development and validation of a sensitive LC-MS-MS method for the determination of adefovir in human serum and urine: application to a clinical pharmacokinetic study","volume":"54","author":"Zhang","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpba.2015.05.001","article-title":"A LC\u2013MS method to quantify tenofovir urinary concentrations in treated patients","volume":"114","author":"Simiele","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2011.12.003","article-title":"Salting-out homogeneous liquid\u2013liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC\u2013MS","volume":"881\u2013882","author":"Zhao","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0225","doi-asserted-by":"crossref","first-page":"70990","DOI":"10.1039\/C6RA08181A","article-title":"Simultaneous determination of entecavir and lamivudine in rat plasma by UPLC-MS\/MS and its application to a pharmacokinetic study","volume":"6","author":"Jiang","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2017.07.003_bib0230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jpba.2013.08.034","article-title":"How to address the sample preparation of hydrophilic compounds: determination of entecavir in plasma and plasma ultrafiltrate with novel extraction sorbents","volume":"88","author":"Vl\u010dkov\u00e1","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.chroma.2012.03.078","article-title":"Highly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography-ultra-high-performance liquid chromatography-tandem mass spectrometry","volume":"1259","author":"Nov\u00e1kov\u00e1","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2017.07.003_bib0240","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jchromb.2011.02.023","article-title":"LC\u2013ESI\u2013MS\/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study","volume":"879","author":"Challa","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0245","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jpba.2009.02.003","article-title":"A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC\u2013MS\/MS","volume":"49","author":"Zhang","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jchromb.2013.05.008","article-title":"High throughput LC\u2013MS\/MS method for simultaneous determination of tenofovir, lamivudine and nevirapine in human plasma","volume":"931","author":"Valluru","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpba.2015.10.017","article-title":"UHPLC\u2013MS\/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients","volume":"118","author":"De Nicol\u00f2","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0260","doi-asserted-by":"crossref","first-page":"22022","DOI":"10.1039\/C5RA00102A","article-title":"Green sample clean-up based on magnetic multiwalled carbon nanotubes for the determination of lamivudine by high performance liquid chromatography","volume":"5","author":"Wang","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2017.07.003_bib0265","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchromb.2013.04.041","article-title":"Selective extraction of lamivudine in human serum and urine using molecularly imprinted polymer technique","volume":"931","author":"Shekarchi","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpba.2013.08.033","article-title":"Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC\u2013MS\/MS","volume":"88","author":"Zheng","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0275","doi-asserted-by":"crossref","first-page":"e0154421","DOI":"10.1371\/journal.pone.0154421","article-title":"Lamivudine concentration in hair and prediction of virologic failure and drug resistance among HIV patients receiving free ART in China","volume":"11","author":"Yan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2017.07.003_bib0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2017.03.020","article-title":"Ultra-performance liquid chromatography tandem mass spectrometry for determination of direct acting antiviral drugs in human liver fine needle aspirates","volume":"1052","author":"Ocque","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2014.02.028","article-title":"Determination of simeprevir: a novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"958","author":"Vanwelkenhuysen","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0290","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2016.02.025","article-title":"Validated UPLC\/MS\/MS assay for quantitative bioanalysis of elbasvir in rat plasma and application to pharmacokinetic study","volume":"1015\u20131016","author":"Liu","year":"2016","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jpba.2017.07.003_bib0295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpba.2016.12.019","article-title":"Towards interference free HPLC-SERS for the trace analysis of drug metabolites in biological fluids","volume":"136","author":"Hassanain","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0300","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC-MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jchromb.2015.11.056","article-title":"Simultaneous determination of ledipasvir, sofosbuvir and itsmetabolite in rat plasma by UPLC-MS\/MS and its application to apharmacokinetic study","volume":"1008","author":"Pan","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0310","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/dmd.115.067496","article-title":"Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans","volume":"44","author":"Shen","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2017.07.003_bib0315","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2016.06.004","article-title":"Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS\/MS method: application to fasting and fed bioequivalence studies","volume":"1028","author":"Rezk","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0325","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpba.2015.11.028","article-title":"A highly sensitive and selective LC-MS\/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies","volume":"119","author":"Kandoussi","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0330","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bmc.3690","article-title":"Novel and sensitive UPLC-MS\/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study","volume":"30","author":"Rezk","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2017.07.003_bib0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC-MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0340","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40261-015-0279-5","article-title":"An open-label investigation into drug\u2013drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects","volume":"35","author":"Bifano","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jpba.2017.07.003_bib0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2012.05.028","article-title":"A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine","volume":"1245","author":"Jiang","year":"2012","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2017.07.003_bib0350","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1021\/ac3024558","article-title":"Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay","volume":"84","author":"Jiang","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2017.07.003_bib0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI\u2013MS\/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0360","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2013.01.029","article-title":"A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma","volume":"921\u2013922","author":"Yuan","year":"2013","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0365","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jssc.201501375","article-title":"Quantification of sofosbuvir in human serum by liquid chromatography with negative ionization mass spectrometry using the parent peak and its source-induced fragment: application to a bioequivalence study","volume":"39","author":"Bahrami","year":"2016","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0370","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5740\/jaoacint.16-0021","article-title":"A rapid and optimized LC-MS\/MS method for the simultaneous extraction and determination of Sofosbuvir and Ledipasvir in human plasma","volume":"99","author":"Elkady","year":"2016","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.jpba.2017.07.003_bib0375","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jpba.2016.11.032","article-title":"Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma","volume":"134","author":"Nannetti","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0380","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpba.2016.01.019","article-title":"Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma","volume":"121","author":"Nannetti","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0385","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1128\/AAC.01693-15","article-title":"Validation and application of a liquid chromatography-tandem mass spectrometry method to determine the concentrations of sofosbuvir anabolites in cells","volume":"59","author":"Rower","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.003_bib0390","doi-asserted-by":"crossref","first-page":"98269","DOI":"10.1039\/C5RA20233G","article-title":"Quantitative performance of online SPE-LC coupled to Q-Exactive for the analysis of sofosbuvir in human plasma","volume":"5","author":"Qu","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2017.07.003_bib0395","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0400","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4155\/bio-2016-0005","article-title":"Characterization of matrix effects in developing rugged high-throughput LC-MS\/MS methods for bioanalysis","volume":"8","author":"Li","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2017.07.003_bib0405","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1021\/ac300442v","article-title":"Calculation and mitigation of isotopic interferences in liquid chromatography\u2013mass spectrometry\/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies","volume":"84","author":"Gu","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2017.07.003_bib0410","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0415","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2017.07.003_bib0420","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","article-title":"HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment","volume":"368","author":"Simon","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.07.003_bib0425","first-page":"1405","article-title":"Viral sequence diversity: challenges for AIDS vaccine designs, Expert Rev","volume":"7","author":"McBurney","year":"2008","journal-title":"Vaccines"},{"key":"10.1016\/j.jpba.2017.07.003_bib0430","unstructured":"WHO, Mother-to-child transmission of HIV, http:\/\/www.who.int\/hiv\/topics\/mtct\/en\/ (Accessed 25.04.17)."},{"key":"10.1016\/j.jpba.2017.07.003_bib0435","unstructured":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf. (Accessed 25.04.17)."},{"key":"10.1016\/j.jpba.2017.07.003_bib0440","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1073\/pnas.91.9.3911","article-title":"Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1","volume":"91","author":"Smerdon","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2017.07.003_bib0445","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0969-2126(01)00168-X","article-title":"Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution","volume":"3","author":"Ding","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.jpba.2017.07.003_bib0450","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nsb0595-407","article-title":"Structure of HIV-1 RT\/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors","volume":"2","author":"Ding","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0455","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.36.12.2664","article-title":"3\u2019-Azido-3\u2019-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors","volume":"36","author":"Larder","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.003_bib0460","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services., http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. (Accessed 26.04.17)."},{"key":"10.1016\/j.jpba.2017.07.003_bib0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jpba.2017.07.003_bib0470","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2017.07.003_bib0475","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2017.07.003_bib0480","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.07.003_bib0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jpba.2017.07.003_bib0490","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0495","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0500","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2017.07.003_bib0505","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-Molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-Human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.003_bib0510","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMe0806598","article-title":"A new class of anti-HIV therapy and new challenges","volume":"359","author":"Dolin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0515","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection","volume":"359","author":"F\u00e4tkenheuer","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0520","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.07.003_bib0525","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/COH.0b013e328322402e","article-title":"HIV-1 entry inhibitors: an overview","volume":"4","author":"Kuritzkes","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jpba.2017.07.003_bib0530","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40121-015-0061-2","article-title":"Drug\u2013drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications","volume":"4","author":"Kaur","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jpba.2017.07.003_bib0535","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2016.04.048","article-title":"Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC\u2013MS\/MS assay","volume":"1025","author":"Blakney","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.07.003_bib0540","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cca.2014.03.016","article-title":"The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood","volume":"433","author":"Marzinke","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2017.07.003_bib0545","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/bmc.2718","article-title":"Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study","volume":"26","author":"Nirogi","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2017.07.003_bib0550","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.jchromb.2011.06.032","article-title":"UPLC-MS\/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues","volume":"879","author":"Huang","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0555","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jchromb.2010.03.036","article-title":"Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS\/MS) assay for the simultaneous determination of existing and new antiretroviral compounds","volume":"878","author":"Else","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0560","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma","volume":"138","author":"Simiele","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0565","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2013.08.002","article-title":"Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS\/MS technology","volume":"86","author":"Djerada","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0570","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jpba.2010.10.011","article-title":"A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation","volume":"54","author":"D\u2019Avolio","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0575","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/rcm.3119","article-title":"Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse tr","volume":"21","author":"ter Heine","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2017.07.003_bib0580","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/rcm.3138","article-title":"Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma","volume":"21","author":"Gehrig","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2017.07.003_bib0585","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2013.01.005","article-title":"Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry","volume":"919\u2013920","author":"Kromdijk","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0590","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2017.07.003_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ancr.2015.08.002","article-title":"Cloud point extraction for analysis of antiretrovirals in human plasma by UFLC-ESI\u2013MS\/MS","volume":"6","author":"Hunzicker","year":"2015","journal-title":"Anal. Chem. Res."},{"key":"10.1016\/j.jpba.2017.07.003_bib0600","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.talanta.2016.08.050","article-title":"Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma","volume":"161","author":"Wang","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2017.07.003_bib0605","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jpba.2016.07.040","article-title":"Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS\/MS and its application to a pharmacokinetic study","volume":"129","author":"Prathipati","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.003_bib0610","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.jchromb.2009.07.031","article-title":"A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV","volume":"877","author":"Martin","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0615","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jchromb.2015.08.016","article-title":"Rat dried blood spot analysis of (R, S)-(\u2212)- and (S, R)-(+)- enantiomers of emtricitabin on immobilized tris-(3, 5-dimethylphenyl carbamate) amylose silica as a chiral stationary phase","volume":"1002","author":"Rao","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0620","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jchromb.2014.05.008","article-title":"Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format","volume":"965","author":"Watanabe","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.003_bib0625","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1007\/s00216-013-6818-0","article-title":"Synthesis and evaluation of molecularly imprinted polymeric microspheres for highly selective extraction of an anti-AIDS drug emtricitabine","volume":"405","author":"Lai","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2017.07.003_bib0630","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/j.jchromb.2011.07.045","article-title":"Comprehensive analysis of the intracellular metabolism of antiretroviral nucleosides and nucleotides using liquid chromatography-tandem mass spectrometry and method improvement by using ultra performance liquid chromatography","volume":"879","author":"Coulier","year":"2011","journal-title":"J. Chromatogr. B"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517316916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517316916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:02:00Z","timestamp":1656734520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708517316916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":126,"alternative-id":["S0731708517316916"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.003","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current antiviral drugs and their analysis in biological materials \u2013 Part II: Antivirals against hepatitis and HIV viruses","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}